Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Business And Shares Still Trailing The Market
Sep 15
Have your own idea? Try our Stock Screener
Markets has moved to Discover
You can now access Markets by navigating to Discover and selecting Markets.
Chinese (SSE) Pharma Industry Analysis
UpdatedSep 27, 2024
DataAggregated Company Financials
Companies219
- 7D6.5%
- 3M1.0%
- 1Y-14.9%
- YTD-14.5%
In the last week, the Pharma industry is up 6.5%, with Jiangsu Hengrui Medicine up 14%. Meanwhile, Hunan Jingfeng PharmaceuticalLtd actually underperformed within the industry, shrinking 13% in the last week. In contrast, the industry has lost 15% in the last 12 months. Earnings are forecast to grow by 19% annually.
Industry Valuation and Performance
Has the Chinese Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 27 Sep 2024 | CN¥2.4t | CN¥798.6b | CN¥76.3b | 26.4x | 31.1x | 3x |
| Sun, 25 Aug 2024 | CN¥2.3t | CN¥804.2b | CN¥78.4b | 24.7x | 29.3x | 2.9x |
| Tue, 23 Jul 2024 | CN¥2.4t | CN¥804.8b | CN¥76.5b | 27.7x | 31.4x | 3x |
| Thu, 20 Jun 2024 | CN¥2.5t | CN¥805.5b | CN¥74.6b | 27.5x | 33.1x | 3.1x |
| Sat, 18 May 2024 | CN¥2.8t | CN¥821.8b | CN¥77.5b | 30.4x | 35.5x | 3.3x |
| Mon, 15 Apr 2024 | CN¥2.6t | CN¥829.0b | CN¥78.5b | 27.9x | 32.6x | 3.1x |
| Wed, 13 Mar 2024 | CN¥2.6t | CN¥832.1b | CN¥80.6b | 28.3x | 32.7x | 3.2x |
| Fri, 09 Feb 2024 | CN¥2.5t | CN¥831.3b | CN¥81.1b | 25x | 30.3x | 3x |
| Sun, 07 Jan 2024 | CN¥2.8t | CN¥830.9b | CN¥79.7b | 30.9x | 34.6x | 3.3x |
| Tue, 05 Dec 2023 | CN¥2.9t | CN¥819.4b | CN¥78.7b | 31.8x | 36.5x | 3.5x |
| Thu, 02 Nov 2023 | CN¥2.8t | CN¥821.4b | CN¥78.2b | 31.2x | 35.9x | 3.4x |
| Sat, 30 Sep 2023 | CN¥2.8t | CN¥824.9b | CN¥78.6b | 32.3x | 35.8x | 3.4x |
| Mon, 28 Aug 2023 | CN¥2.6t | CN¥820.0b | CN¥78.5b | 29.2x | 32.8x | 3.1x |
| Wed, 26 Jul 2023 | CN¥2.8t | CN¥810.8b | CN¥76.9b | 32.8x | 36.3x | 3.4x |
| Fri, 23 Jun 2023 | CN¥2.8t | CN¥809.7b | CN¥76.5b | 31.3x | 36.4x | 3.4x |
| Sun, 21 May 2023 | CN¥3.0t | CN¥809.1b | CN¥76.5b | 33.9x | 39.4x | 3.7x |
| Tue, 18 Apr 2023 | CN¥3.0t | CN¥799.3b | CN¥89.9b | 35x | 33.9x | 3.8x |
| Thu, 16 Mar 2023 | CN¥2.9t | CN¥780.1b | CN¥83.7b | 38.2x | 34.8x | 3.7x |
| Sat, 11 Feb 2023 | CN¥2.9t | CN¥774.5b | CN¥83.0b | 36.1x | 35.1x | 3.8x |
| Mon, 09 Jan 2023 | CN¥2.8t | CN¥772.3b | CN¥82.1b | 33.9x | 33.8x | 3.6x |
| Wed, 07 Dec 2022 | CN¥2.8t | CN¥767.8b | CN¥81.9b | 36x | 34.1x | 3.6x |
| Fri, 04 Nov 2022 | CN¥2.7t | CN¥767.3b | CN¥81.7b | 34.6x | 33.1x | 3.5x |
| Sun, 02 Oct 2022 | CN¥2.4t | CN¥760.3b | CN¥79.5b | 30.4x | 30.3x | 3.2x |
| Tue, 30 Aug 2022 | CN¥2.6t | CN¥759.2b | CN¥81.1b | 30.8x | 31.6x | 3.4x |
| Thu, 28 Jul 2022 | CN¥2.7t | CN¥744.7b | CN¥81.1b | 31.5x | 33.1x | 3.6x |
| Sat, 25 Jun 2022 | CN¥2.7t | CN¥739.5b | CN¥81.9b | 32.3x | 33.5x | 3.7x |
| Mon, 23 May 2022 | CN¥2.6t | CN¥740.3b | CN¥81.7b | 32.8x | 31.8x | 3.5x |
| Wed, 20 Apr 2022 | CN¥2.6t | CN¥727.0b | CN¥75.7b | 32.1x | 34.8x | 3.6x |
| Fri, 18 Mar 2022 | CN¥2.8t | CN¥727.0b | CN¥77.8b | 33x | 36.6x | 3.9x |
| Sun, 13 Feb 2022 | CN¥2.7t | CN¥721.5b | CN¥73.6b | 31.9x | 36.5x | 3.7x |
| Tue, 11 Jan 2022 | CN¥3.2t | CN¥720.2b | CN¥73.5b | 38.1x | 43.1x | 4.4x |
| Thu, 09 Dec 2021 | CN¥3.0t | CN¥718.2b | CN¥73.2b | 31.5x | 41.2x | 4.2x |
| Sat, 06 Nov 2021 | CN¥2.8t | CN¥716.8b | CN¥73.0b | 29.4x | 38.6x | 3.9x |
| Mon, 04 Oct 2021 | CN¥2.9t | CN¥704.1b | CN¥73.0b | 31.1x | 39.1x | 4.1x |
Price to Earnings Ratio
39.1x
Current Industry PE
- Investors are pessimistic on the Chinese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 31.1x which is lower than its 3-year average PE of 34.6x.
- The 3-year average PS ratio of 3.5x is higher than the industry's current PS ratio of 3.0x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have grown 4.3% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 9.62% | |
| Healthcare | 7.00% | |
| Pharma | 6.49% | |
| Pharma | 6.49% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 600276 Jiangsu Hengrui Medicine | CN¥48.68 | 14.0% +CN¥38.0b | 8.3% | PE57x | |
| 600436 Zhangzhou Pientzehuang Pharmaceutical | CN¥234.99 | 16.9% +CN¥20.5b | -14.6% | PE47.6x | |
| 000538 Yunnan Baiyao GroupLtd | CN¥56.47 | 12.5% +CN¥11.2b | 5.9% | PE22.6x | |
| 600085 Beijing Tongrentang | CN¥38.24 | 19.9% +CN¥8.7b | -30.2% | PE30.8x | |
| 000661 Changchun High-Tech Industry (Group) | CN¥99.90 | 24.8% +CN¥8.0b | -28.1% | PE9.8x |
